Displaying drugs 2276 - 2300 of 3223 in total
GTI 2040
GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.
Investigational
IMO-2055
Investigational
GTI-2040
GTI-2040 is under investigation in clinical trial NCT00084643 (GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors).
Investigational
TNP-2092
TNP-2092 is under investigation in clinical trial NCT03964493 (TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection).
Investigational
Matched Iupac: … ]methylidene}amino]piperidin-4-yl}(methyl)amino)cyclopropyl]pyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9- …
APR-2020
APR-2020 is a CD34+ cells that have been transduced in vitro with a lentiviral vector carrying a codon-optimized sequence for expressing the wild type RPS19 protein
Investigational
EGT-301
EGT-301 is a gene therapy being investigated for Hunter Syndrome. It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome.
Investigational
Matched Description: … It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase …
LY-2090314
Ly2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.
Investigational
BAL200
Investigational
OAV201
OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter. It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical...
Investigational
Matched Description: … OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human …
ECT204
ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Investigational
Sri-9439
Experimental
CRA_9076
Experimental
CRA_9678
Experimental
DP-b99
DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Investigational
AZD-9056
AZD9056 has been used in trials studying the basic science and treatment of Rheumatoid Arthritis.
Investigational
AZD-9496
AZD-9496 is under investigation in clinical trial NCT02248090 (AZD9496 First Time in Patients Ascending Dose Study).
Investigational
CP-96345
Experimental
ZK-93423
ZK-93423 is a beta-carboline with muscle relaxant activity with agonistic properties at the benzodiazepine receptor.
Investigational
BLU-9931
Investigational
CC-90001
Investigational
Hydroxydione
Hydroxydione (Viadril) is a neuroactive steroid used as a general anesthetic.
Investigational
Withdrawn
VTP-201227
VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications. It is being developed by Vitae Pharmaceuticals.
Investigational
Displaying drugs 2276 - 2300 of 3223 in total